Navigation Links
Cancer Risk After Kidney Transplant Unaffected by Type of Drug Treatment
Date:4/29/2010

Risk similar from all drugs used to prevent organ rejection, researchers find

THURSDAY, April 29 (HealthDay News) -- The type of drug treatment used to prevent organ rejection in kidney transplant patients doesn't affect cancer risk, a new study finds.

Kidney transplant patients are at increased risk for cancer, likely because of patients' long-term use of immunosuppressive drugs to prevent organ rejection. In this study, Australian researchers examined the incidence of cancer in 481 kidney transplant patients.

The patients had received one of three treatment regimens: azathioprine and prednisolone; cyclosporine monotherapy; or cyclesoporine monotherapy followed by a switch to azathioprine and prednisolone after three months.

In the 20 years after transplant, 226 patients developed at least one cancer, including 48 percent who developed skin cancer and 27 percent who developed non-skin cancer. None of the anti-rejection treatments had a greater effect than another on cancer timing or incidence.

The findings indicate that "any differences in cancer risk from these different treatments are unlikely to be clinically significant," said study author Martin Gallagher, of the George Institute for International Health in Australia.

He and his colleagues also found that kidney transplant recipients' increased risk of cancer is significantly influenced by certain characteristics at the time of transplant. For example, non-skin cancer is associated with increasing age and previous smoking history, while skin cancer is associated with increasing age, non-brown eye color, fairer skin, and a functioning transplant.

High-risk patients need to be monitored more closely and use preventive measures to protect against cancer, the researchers said.

The study appears in the April 29 issue of the Journal of the American Society of Nephrology.

More information

The National Kidney Foundation has more about reducing cancer risk after a kidney transplant.



-- Robert Preidt



SOURCE: American Society of Nephrology, news release, April 29, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Cells programmed to cure and even prevent cancer
2. FDA Approval of new Prostate Treatment Shows Promise of Cancer Immunotherapy
3. Prostate Cancer Vaccine Gains FDA Approval
4. CXCR4: A new drug target in lung cancer
5. Best care for the oldest lung cancer patients
6. Curcumin nanoparticles open up resistant cancers
7. Oncos Therapeutics raises €4 million ($5.3 million) to develop oncolytic viruses into cancer treatment
8. Breakthrough in Predicting Invasive Breast Cancer
9. Comparison of available breast cancer risk assessment tools shows room for improvement
10. Breakthrough method predicts risk of invasive breast cancer
11. Researchers attack stem cells that cause colon cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, ... at his family verbally and physically. , “When something upset him, he couldn’t control his ... it. He would throw rocks at my other children and say he was going to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda ... orthodontic treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including ... accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Collagen Matrix, Inc., ("Collagen Matrix") the driving ... collagen and mineral based medical devices for tissue ... Messer has joined the company as Vice ... growing portfolio of oral surgery, neurosurgery, orthopaedic and ... the Collagen Matrix executive team as an accomplished ...
(Date:6/24/2016)... June 24, 2016 The Academy of Managed ... recommendations that would allow biopharmaceutical companies to more ... that make formulary and coverage decisions, a move that ... new medicines. The recommendations address restrictions in ... on the drug label, a prohibition that hinders decision ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
Breaking Medicine Technology: